Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Esther E., White, Richard G., Bakker, Roel, Orroth, Kate K., Weiss, Helen A., Buvé, Anne, Hayes, Richard J., Glynn, Judith R.
Formato: Texto
Lenguaje:English
Publicado: Elsevier Science 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686080/
https://www.ncbi.nlm.nih.gov/pubmed/19071187
http://dx.doi.org/10.1016/j.vaccine.2008.11.074
Descripción
Sumario:Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30–40% after 20 years (range 4–66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.

Ejemplares similares